Plan sponsors should be aware of the important health implications the “fourth trimester” of pregnancy holds for new mothers.

By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.

More than half of U.S. adults suffer from cardiovascular disease, diabetes or obesity and a growing number experience all three. Plan sponsors can take action to address this increasingly complex challenge.

Pregnant individuals require routine, dedicated care to ensure positive parental and fetal outcomes.

GLP-1 medications are FDA-approved specifically for weight loss for more than half the adult population of the United States. Plan sponsors can take action to manage weight and other cardiodiabesity-related health challenges within their member population.

A report from the Evernorth Research Institute offers insights that can help health plans optimize cancer care.

To create a strong pipeline of early career technology talent, and create equitable opportunities for underrepresented students, Evernorth has partnered with Access Point – a program designed to provide accelerated hands-on technical training and mentorship.

We are taking a thoughtful and comprehensive approach to assessing biosimilar options that considers several factors.